Researchers uncovered how herpes simplex virus type 1 reprograms human chromatin structure by hijacking transcriptional machinery, potentially revealing a new antiviral target.
FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.
New 2024 EULAR recommendations offer evidence-based guidance for the use of antirheumatic drugs during pregnancy, lactation, and conception planning in patients with rheumatic and musculoskeletal diseases.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.
May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.